No Drug

Phase 2Small molecule

Daiichi Sankyo

No Drug is one of 131 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

PreeclampsiaActive, not recruiting

Multiple SclerosisActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Triple-Negative Breast CancerPreclinical

Active, not recruiting

PreeclampsiaPhase 2/Phase 3

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Betaseron

Bayer

Preclinical

16 2

Kesimpta

Novartis

Preclinical

15 3

Tysabri

Biogen

Preclinical

14 4

No Drug

Daiichi Sankyo

Phase 2

1 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Flomax

Sanofi

Preclinical

1 8

Pred Forte

Myfortic

Novantrone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Not yet recruiting

Multiple Sclerosis

NCT07149662

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

Unknown status·RRamathibodi Hospital·Phase 2·NCT01364688·80 enrolled

Preeclampsia1 trial

PP13 and Doppler Study to Predict Preeclampsia

Unknown status·—·Phase 2/3·NCT00928213·1,000 enrolled

Multiple Sclerosis1 trial

Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy

Not yet recruiting·RRegion Stockholm··NCT07149662·111 enrolled

Triple-Negative Breast Cancer1 trial

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo··NCT07092254·760 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for No Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — No Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for No Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Daiichi Sankyo

No Drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Chronic Kidney Disease1 trial

Preeclampsia1 trial

Multiple Sclerosis1 trial

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News